These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31267152)

  • 1. Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson's disease.
    Miyata M; Kakeda S; Toyoshima Y; Ide S; Okada K; Adachi H; Wang Y; Korogi Y
    Neuroradiology; 2019 Nov; 61(11):1251-1259. PubMed ID: 31267152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal intensity of cerebral gyri in corticobasal syndrome on phase difference enhanced magnetic resonance images: Comparison of progressive supranuclear palsy and Parkinson's disease.
    Miyata M; Kakeda S; Yoneda T; Ide S; Okada K; Adachi H; Korogi Y
    J Neurol Sci; 2020 Dec; 419():117210. PubMed ID: 33130433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration.
    Santos-Santos MA; Mandelli ML; Binney RJ; Ogar J; Wilson SM; Henry ML; Hubbard HI; Meese M; Attygalle S; Rosenberg L; Pakvasa M; Trojanowski JQ; Grinberg LT; Rosen H; Boxer AL; Miller BL; Seeley WW; Gorno-Tempini ML
    JAMA Neurol; 2016 Jun; 73(6):733-42. PubMed ID: 27111692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson's disease.
    Azuma M; Hirai T; Nakaura T; Kitajima M; Yamashita S; Hashimoto M; Yamada K; Uetani H; Yamashita Y; Wang Y
    J Neurol Sci; 2019 Nov; 406():116443. PubMed ID: 31634718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voxel-based morphometry in autopsy proven PSP and CBD.
    Josephs KA; Whitwell JL; Dickson DW; Boeve BF; Knopman DS; Petersen RC; Parisi JE; Jack CR
    Neurobiol Aging; 2008 Feb; 29(2):280-9. PubMed ID: 17097770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration.
    Wakabayashi K; Takahashi H
    Neuropathology; 2004 Mar; 24(1):79-86. PubMed ID: 15068177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration.
    Gröschel K; Hauser TK; Luft A; Patronas N; Dichgans J; Litvan I; Schulz JB
    Neuroimage; 2004 Feb; 21(2):714-24. PubMed ID: 14980574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy.
    Boxer AL; Geschwind MD; Belfor N; Gorno-Tempini ML; Schauer GF; Miller BL; Weiner MW; Rosen HJ
    Arch Neurol; 2006 Jan; 63(1):81-6. PubMed ID: 16401739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration.
    Yoshida M
    Neuropathology; 2014 Dec; 34(6):555-70. PubMed ID: 25124031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-occurrence of radiological features of progressive supranuclear palsy and corticobasal degeneration.
    Divatia R; Khan F; Kishore A
    Neurol India; 2007; 55(1):75-7. PubMed ID: 17272907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy.
    Komori T; Arai N; Oda M; Nakayama H; Mori H; Yagishita S; Takahashi T; Amano N; Murayama S; Murakami S; Shibata N; Kobayashi M; Sasaki S; Iwata M
    Acta Neuropathol; 1998 Oct; 96(4):401-8. PubMed ID: 9797005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration.
    Dickson DW
    J Neurol; 1999 Sep; 246 Suppl 2():II6-15. PubMed ID: 10525997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD.
    Kashihara K; Shinya T; Higaki F
    Intern Med; 2011; 50(16):1683-7. PubMed ID: 21841326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Corticobasal degeneration and atypical progressive supranuclear palsy: their symptomatology, laboratory examination and differential diagnosis].
    Morimatsu M; Negoro K; Mori H
    Rinsho Shinkeigaku; 2004 Nov; 44(11):982-5. PubMed ID: 15651349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of astrocytic plaques in the corticobasal degeneration brain and comparison with tuft-shaped astrocytes in the progressive supranuclear palsy brain.
    Hattori M; Hashizume Y; Yoshida M; Iwasaki Y; Hishikawa N; Ueda R; Ojika K
    Acta Neuropathol; 2003 Aug; 106(2):143-9. PubMed ID: 12732936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glial abnormalities in progressive supranuclear palsy and corticobasal degeneration].
    Zhu MW; Wang LN; Li XH; Gui QP
    Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):125-9. PubMed ID: 15132848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A 65-year-old man with rigid-bradykinetic parkinsonism, vertical gaze palsy, difficulty of eye-lid opening, and marked pseudo-bulbar palsy].
    Noda K; Kobayashi T; Matsuoka S; Takanashi M; Kanazawa A; Mizuno Y
    No To Shinkei; 2005 Jan; 57(1):73-86. PubMed ID: 15782604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD).
    Swallow DMA; Counsell CE
    J Neurol; 2023 Jul; 270(7):3464-3474. PubMed ID: 36971841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case of Pathologically Confirmed Corticobasal Degeneration Initially Presenting as Progressive Supranuclear Palsy Syndrome.
    Chung EJ; Cho HJ; Jang W; Hur DY; Kim YS; Lee KH; Kim SJ
    J Korean Med Sci; 2022 Jun; 37(22):e183. PubMed ID: 35668689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
    Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
    Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.